VITA 34 AG Share Price

Equities

V3V

DE000A0BL849

Healthcare Facilities & Services

Market Closed - Xetra 16:36:10 26/04/2024 BST 5-day change 1st Jan Change
5.15 EUR +6.40% Intraday chart for VITA 34 AG +15.99% -1.72%

Financials

Sales 2023 * 76.8M 82.12M 6.58B Sales 2024 * 79.1M 84.58M 6.77B Capitalization 89.77M 95.99M 7.69B
Net income 2023 * -4M -4.28M -342M Net income 2024 * -2M -2.14M -171M EV / Sales 2023 * 1.33 x
Net Debt 2023 * 12M 12.83M 1.03B Net Debt 2024 * 6.6M 7.06M 565M EV / Sales 2024 * 1.22 x
P/E ratio 2023 *
-21.5 x
P/E ratio 2024 *
-42.9 x
Employees 815
Yield 2023 *
-
Yield 2024 *
-
Free-Float 30.42%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.40%
1 week+15.99%
Current month+3.41%
1 month+13.94%
3 months-2.46%
6 months+12.94%
Current year-1.72%
More quotes
1 week
4.62
Extreme 4.62
5.15
1 month
4.38
Extreme 4.38
5.90
Current year
3.69
Extreme 3.69
5.90
1 year
3.69
Extreme 3.69
7.30
3 years
3.69
Extreme 3.69
17.95
5 years
3.69
Extreme 3.69
17.95
10 years
3.55
Extreme 3.551
18.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 21/03/22
Director of Finance/CFO - 31/07/22
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 49 30/06/20
Chairman 59 14/12/21
Director/Board Member 51 -
More insiders
Date Price Change Volume
26/04/24 5.15 +6.40% 1,252
25/04/24 4.84 -3.20% 961
24/04/24 5 -0.99% 820
23/04/24 5.05 +5.21% 1,922
22/04/24 4.8 +8.11% 2,450

Delayed Quote Xetra, April 26, 2024 at 04:36 pm

More quotes
Vita 34 International AG is a Germany-based company engaged in the medical technology sector. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The Company acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.15 EUR
Average target price
5.3 EUR
Spread / Average Target
+2.91%
Consensus

Quarterly revenue - Rate of surprise